ProQR Therapeutics (PRQR) Consolidated Net Income (2021 - 2025)
Historic Consolidated Net Income for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$13.2 million.
- ProQR Therapeutics' Consolidated Net Income fell 3781.35% to -$13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$49.2 million, marking a year-over-year decrease of 6988.18%. This contributed to the annual value of -$30.0 million for FY2024, which is 15.84% down from last year.
- Per ProQR Therapeutics' latest filing, its Consolidated Net Income stood at -$13.2 million for Q3 2025, which was down 3781.35% from -$13.9 million recorded in Q2 2025.
- In the past 5 years, ProQR Therapeutics' Consolidated Net Income registered a high of -$3.9 million during Q2 2024, and its lowest value of -$20.0 million during Q3 2022.
- Moreover, its 5-year median value for Consolidated Net Income was -$12.7 million (2022), whereas its average is -$12.7 million.
- As far as peak fluctuations go, ProQR Therapeutics' Consolidated Net Income skyrocketed by 5974.5% in 2023, and later crashed by 25765.03% in 2025.
- Over the past 5 years, ProQR Therapeutics' Consolidated Net Income (Quarter) stood at -$19.8 million in 2021, then surged by 35.87% to -$12.7 million in 2022, then soared by 46.95% to -$6.7 million in 2023, then tumbled by 59.73% to -$10.8 million in 2024, then fell by 22.46% to -$13.2 million in 2025.
- Its Consolidated Net Income was -$13.2 million in Q3 2025, compared to -$13.9 million in Q2 2025 and -$11.4 million in Q1 2025.